- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04680936
Low and High Dose Dextrose Prolotherapy in the Treatment of Lateral Epicondylitis
Is Low Dose Dextrose Prolotherapy as Effective as High Dose Dextrose Prolotherapy in the Treatment of Lateral Epicondylitis?- A Double Blind- Ultrasound Guided- Randomized Controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Lateral epicondylitis (tennis elbow) is an enthesopathy seen in 1-2% of the population aged 30-65 years, which can occur in the lateral epicondyle origo of the extensor carpi radialis brevis and longus muscles, after frequently repetitive activities and can lead to limitations in the daily life activities of the patients.
The diagnosis is made by anamnesis and clinical examination, cases that last more than 3 months are defined as chronic lateral epicondylitis.
Treatment options are analgesics, non-steroidal anti-inflammatory drugs, hand-wrist splints, eccentric strengthening exercises for forearm muscles and wrist dorsiflexors, injection therapies, physical therapy agents such as therapeutic ultrasound, ESWT(extracorporeal shockwave therapy), low-level laser therapy, and surgery.
Prolotherapy is a treatment method that is performed with repetitive injections of a small amount of irritant or sclerosing solutions such as hypertonic dextrose, phenol-glycerin-glucose, or sodium morrhuate and aims to activate the healing process by increasing the blood flow around the damaged tendinopathy or enthesopathy area with the effect of these solutions. Hypertonic dextrose solutions in concentrations ranging from 12.5-20% are frequently used in prolotherapy.
Dextrose is an ideal proliferant agent due to its ability to dissolve in water, exists in the blood chemically, and to led safely apply to more than one place. It is known that hypertonic dextrose solutions dehydrate the cells in the injection area, cause local tissue trauma, attracts granulocytes and macrophages to the damaged area, and triggers healing. Prolotherapy can be done with ultrasound guidance or by determining anatomical landmarks. The injection is applied to the annular ligament, lateral epicondyle, and supracondylar area where the forearm extensor muscles adhere. Injection side effects and complications are pain, bruising, muscle spasm, nerve or vessel damage at the injection site.
Based on previous studies, the low dose of dextrose solutions (1%, 5%, and 10%) may have a similar effect with fewer side effects than higher concentrations of dextrose solutions (15%, 20%, 25%) and the low dose may have fewer cell damage. Thus, it may be possible to apply an effective treatment method with fewer side effects in the treatment of lateral epicondylitis. Also, in this study, the effect of inflammation created by injection of saline in one group and the inflammatory, proliferative and angiogenic effects of dextrose injected in other groups at different concentrations on the treatment outcome will be compared.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Kırşehir, Turkey
- Kirsehir Ahi Evran University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Those who admit Kirsehir Ahi Evran University Hospital and is diagnosed with lateral epicondylitis,
- Participants with unilateral or bilateral lateral epicondylitis and pain and functional limitations due to this condition,
- who can read and write in Turkish,
- participant's admission participating in the study,
- participants who do not have exclusion criteria,
Exclusion Criteria:
- receiving any injection therapy to the elbow area in the last 3 months,
- participants with complaints less than 3 months(acute lateral epicondylitis)
- previously surgery on the elbow area,
- having a history of acute trauma or fracture in the elbow area,
- have local dermatological problems,
- have a local infection in the treatment area,
- those who are allergic to dextrose,
- with coagulation disorders or using anticoagulant drugs,
- with an autoimmune disease,
- with type 1 or type 2 diabetes mellitus,
- have unregulated hypertension,
- have immune dysfunction,
- with malignancy or diagnosed with a malignancy in the last 5 years,
- pregnancy or lactation,
- having cervical radiculopathy in the same extremity,
- with cognitive dysfunction,
- patients with paralysis in the same extremity,
- lack of cooperation due to cognitive impairment,
- participant's refusal to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: low dose dextrose arm (5% dextrose)
Prolotherapy injection will be made with 5% dextrose solution for 3 sessions with 3 weeks intervals.
1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions.
Before the treatment, the examination and questionnaire data of the patient will be recorded.
|
low dose dextrose solution
Other Names:
|
Active Comparator: high dose dextrose arm (15% dextrose)
Prolotherapy injection will be made with 15% dextrose solution for 3 sessions with 3 weeks intervals.
1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions.
Before the treatment, the examination and questionnaire data of the patient will be recorded.
|
high dose dextrose solution
Other Names:
|
Active Comparator: Isotonic saline arm (0.9% NaCl)
Prolotherapy injection will be made with isotonic saline for 3 sessions with 3 weeks intervals.
1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions.
Before the treatment, the examination and questionnaire data of the patient will be recorded.
|
isotonic saline solution
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the effect of prolotherapy injection on hand grip strength.
Time Frame: Change of the hand grip strength at baseline, 3 weeks and after the injection treatment (12th week).
|
Evaluation of the effect of prolotherapy injection on hand grip strength Hand grip strength will be measured with Hand-Dynamometer, before injection treatment (pre-intervention), at the 3rd week (2nd session of treatment) and after the injection treatment (12th week).
|
Change of the hand grip strength at baseline, 3 weeks and after the injection treatment (12th week).
|
Evaluation of elbow pain that develops at rest and movement before, during and after injection treatment.
Time Frame: Change in elbow pain at baseline, 3 weeks and after the injection treatment (12th week).
|
Elbow pain at rest and movement will be assessed by Visual Analogue Scale, before injection treatment (pre-intervention), at the 3rd week (2nd session of treatment) and after the injection treatment (12th week).
|
Change in elbow pain at baseline, 3 weeks and after the injection treatment (12th week).
|
Evaluation of elbow pain threshold, before, during and after injection treatment.
Time Frame: Change in elbow pain threshold at baseline, 3 weeks and after the injection treatment (12th week).
|
Elbow pain threshold will be assessed by Pain Algometer, before injection treatment (pre-intervention), at the 3rd week (2nd session of treatment) and after the injection treatment (12th week).
|
Change in elbow pain threshold at baseline, 3 weeks and after the injection treatment (12th week).
|
Assessment of the effect of elbow pain on daily life activities.
Time Frame: Change of the effect of elbow pain on daily life activities at baseline, 3 weeks and after the injection treatment (12th week).
|
Daily life activities will be measured with Quick-DASH(Disabilities of Arm, Shoulder and Hand) Questionnaire, before injection treatment (pre-intervention), at the 3rd week (2nd session of treatment) and after the injection treatment (12th week).
|
Change of the effect of elbow pain on daily life activities at baseline, 3 weeks and after the injection treatment (12th week).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the clinical improvement.
Time Frame: week 3 and 12
|
Clinical improvement of the patients will be evaluated subjectively with the Global Disease Assessment Questionnaire, before injection treatment (pre-intervention), at the 3rd week (2nd session of treatment) and after the injection treatment (12th week).
|
week 3 and 12
|
Evaluation of the injection side effects and complications.
Time Frame: 12 weeks
|
Side effects and complications that may occur after injection treatments will be evaluated and compared between groups.
|
12 weeks
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Hauser RA, Lackner JB, Steilen-Matias D, Harris DK. A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain. Clin Med Insights Arthritis Musculoskelet Disord. 2016 Jul 7;9:139-59. doi: 10.4137/CMAMD.S39160. eCollection 2016.
- Sims SE, Miller K, Elfar JC, Hammert WC. Non-surgical treatment of lateral epicondylitis: a systematic review of randomized controlled trials. Hand (N Y). 2014 Dec;9(4):419-46. doi: 10.1007/s11552-014-9642-x.
- Tsai SW, Hsu YJ, Lee MC, Huang HE, Huang CC, Tung YT. Effects of dextrose prolotherapy on contusion-induced muscle injuries in mice. Int J Med Sci. 2018 Jul 30;15(11):1251-1259. doi: 10.7150/ijms.24170. eCollection 2018.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lateral Epicondylitis
-
Hospital for Special Surgery, New YorkActive, not recruitingLateral Epicondylitis | Lateral Epicondylitis, Unspecified Elbow | Lateral Epicondylitis, Left Elbow | Lateral Epicondylitis, Right Elbow | Lateral Epicondylitis (Tennis Elbow) Bilateral | Medial Epicondylitis | Medial Epicondylitis, Right Elbow | Medial Epicondylitis, Left ElbowUnited States
-
Singapore General HospitalNot yet recruitingLateral Epicondylitis, Unspecified Elbow
-
McMaster UniversityArthrex, Inc.; The Physicians' Services Incorporated Foundation; Radiological...TerminatedLateral Epicondylitis (Tennis Elbow)Canada, United States
-
Haseki Training and Research HospitalCompletedLateral Epicondylitis (Tennis Elbow)Turkey
-
Siddharth Padia, MDRecruiting
-
University of CadizNot yet recruitingElbow Tendinopathy | Epicondylitis | Epicondylitis, Lateral | Epicondylitis of the Elbow
-
Chuncheon Sacred Heart HospitalRecruitingLateral Epicondylitis of ElbowKorea, Republic of
-
Uskudar State HospitalRecruitingLateral Epicondylitis | Lateral Epicondylitis, Unspecified ElbowTurkey
-
Istanbul Training and Research HospitalCompletedLateral Epicondylitis | Comparing Autologous Blood Corticosteroid and Their Combined Injection for Treating Lateral EpicondylitisTurkey
-
Mennallah Ahmed Mohamed Anwar ElgendyNot yet recruiting
Clinical Trials on Dextrose 5% in water
-
Mast Therapeutics, Inc.Terminated
-
National Cheng-Kung University HospitalRecruitingMyofascial Trigger Point PainTaiwan
-
Tranzyme, Inc.CompletedPostoperative IleusUnited States, India, Romania
-
Tranzyme, Inc.CompletedDiabetes Mellitus | GastroparesisUnited States, Denmark, Norway, Sweden, United Kingdom, India
-
Tranzyme, Inc.NorgineCompletedGastrointestinal DysmotilityUnited States, United Kingdom, Serbia, Italy, Romania, Hungary, Poland
-
Tranzyme, Inc.CompletedDiabetes Mellitus | GastroparesisSweden, Denmark
-
Universidad Abierta InteramericanaUnknownSuperficial Radial Nerve LesionArgentina
-
Kastamonu UniversityCompleted
-
National Bioethics Commission of BrazilCompletedRetinopathy of PrematurityBrazil
-
John A. SchirgerNational Institutes of Health (NIH)WithdrawnHeart Failure | Renal Insufficiency